Clinical Trial: NCT05182957
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
Status:
RECRUITINGPhase:
Phase 2| Lead Sponsor: | The First Affiliated Hospital of Soochow University |
| Information Provided By: | The First Affiliated Hospital of Soochow University |
| Last Update Posted: | 2026-05-01 |
Study Overview
Brief Summary
Aim of this study will evaluate the Efficacy and Safety of Anti-PD-1 monoclonal antibody Combined Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma Patients.
Official Title
Clinical Study on the Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Combined Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
Conditions
Relapsed/Refractory Peripheral T-cell Lymphoma
Intervention / Treatment
- Drug: Anti-PD-1 monoclonal antibody
- Drug: Lenalidomide
- Drug: Azacitidine
Other Study ID Numbers
- R/R PTCL 01
Start Date (Actual)
2020-01-01
Primary Completion Date (Actual)
2023-12-15
Study Completion Date (Estimated)
2026-06-15
Enrollment (Estimated)
31
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | The First Affiliated Hospital of Soochow University |
| Information Provided By: | The First Affiliated Hospital of Soochow University |
| Last Update Posted: | 2026-05-01 |
Study Overview
Brief Summary
Aim of this study will evaluate the Efficacy and Safety of Anti-PD-1 monoclonal antibody Combined Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma Patients.
Official Title
Clinical Study on the Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Combined Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
Conditions
Relapsed/Refractory Peripheral T-cell Lymphoma
Intervention / Treatment
- Drug: Anti-PD-1 monoclonal antibody
- Drug: Lenalidomide
- Drug: Azacitidine
Other Study ID Numbers
- R/R PTCL 01
Start Date (Actual)
2020-01-01
Primary Completion Date (Actual)
2023-12-15
Study Completion Date (Estimated)
2026-06-15
Enrollment (Estimated)
31
Study Type
Interventional
Phase
Phase 2